A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency

Authors

Huang, Y., Nair, M. S., Yu, J., Chong, S., Hong, H., Mohri, H., Takata, H., Varco-Merth, B. D., Marenco, A., Lifson, J. D., Ndhlovu, L., Bowen, A., Trautmann, L., Vasan, S., Chun, T.-W., Okoye, A. A., Ho, D. D.

Abstract

Antiretroviral therapy suppresses HIV-1 replication but cannot eliminate the latent viral reservoir persisting in memory CD4 T cells. Existing latency reversal candidates have yet to achieve robust viral reactivation at tolerable doses. We engineered T4IL15{triangleup}, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation. T4IL15{triangleup} reactivated latent virus in 94% (48/51) of clinical samples ex vivo, 75% (15/20) of administrations in HIV-1-infected and ART-suppressed humanized mice, and 100% (6/6) of SIV-infected and ART-suppressed rhesus macaques at doses well tolerated. We also found that off-target stimulation of non-CD4 cells hindered HIV-1 reactivation ex vivo. T4IL15{triangleup} provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 09 Oct 2026.

Stats

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.